Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036087 | 1.00 | CRBN (0.55) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30798411 | 0.88 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30048741 | 0.87 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27157407 | 0.87 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27157405 | 0.86 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23306591 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL31072968 | 0.85 | CRBN (0.54) | CRBNDDB1GSPT1 | |
| SCHEMBL29712444 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL30180332 | 0.84 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22346841 | 0.84 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4362939-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4329744-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | Neomorph, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4329746-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023278325-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | ALK, JMJD7, ALKBH3 | CRBN 870/4885DDB1 1553/4885ALDH1A1 74/4885 |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | CRBN, IKZF2, IKZF1 | CRBN 1/4885DDB1 276/4885ALDH1A1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.